N/A
Loading page data
Please wait a moment
Loading page data
Please wait a moment
Second Floor, 150 Fleet Street,
London, EC4A 2DQ.
+44 203-837-5656
108 W 39th Street, Ste 1006,
PMB2219, New York, NY 10018
+1 646-878-6329
IT Unit No. 504, 5th Floor, Icon
Tower, Baner, Pune - 411045.
+91 906 779 3500
Peripheral ulcerative keratitis treatment market is growing at a significant rate and growth is primarily attributed to growing aging population, rising prevalence of ophthalmic diseases, increasing company investments for launching new product forms, health conscious population, free eye check-up camps funded by the government in the different regions.
Approximately 50% of the cases are related to a rise in systemic collagen vascular disease. Secondly, raising awareness towards various treatment options for peripheral ulcerative keratitis and rising prevalence of blindness amongst the geriatric population is driving the growth of peripheral ulcerative keratitis treatment market.
Advancements in topical treatment (topical corticosteroids, antibiotics, an immunosuppressive drug, cyclosporine (cyclosporine A), and collagenase synthetase inhibitors), surgical treatment and systemic treatment which includes corticosteroids, immunosuppressive agents, and biologic therapy are some other factors driving the growth of global peripheral ulcerative keratitis treatment market.
However stringent government regulations in various drugs development procedures and the side effects associated with various antibiotics would impede the adoption of eye care treatment, thereby, hamper the market growth.
The global peripheral ulcerative keratitis market is segmented on the basis of product type, distribution channel, and product type
| treatment type |
|
| product type |
|
| distribution channel, |
|
Globally, the peripheral ulcerative keratitis treatment market is expected to witness healthy growth in the near future, due to increasing awareness towards eye care, growing aging population and the rise in per capita expenditure on healthcare in the developing nations.
North America dominates the global peripheral ulcerative keratitis treatment, followed by Europe, owing to technological advancement and more number of market players in these regions. The Asia Pacific market is expected to register the fastest growth owing to the rise in geriatric population and also the rise in prevalence of blindness in geriatric population.
Some of the key market players in global peripheral ulcerative keratitis market are Allergan Inc., Alcon Laboratories Inc., Johnson & Johnson Ltd., Pfizer Inc., Merck & Co., Inc., Novartis, Santen Pharmaceuticals, Valeant Pharmaceuticals Inc., Bayer, GlaxoSmithKline, Sanofi-Aventis and Bausch & Lomb, Inc.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data.
It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology, and applications.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.
The report provides in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
